By Counterforce Health Team in Naglazyme (galsulfase) —

Myths vs. Facts: Getting Naglazyme (galsulfase) Covered by UnitedHealthcare in California

Answer Box: Fast Facts for California Patients

UnitedHealthcare requires prior authorization for Naglazyme (galsulfase) in California. Success depends on complete diagnostic documentation (enzyme assay + genetic testing), specialist involvement, and baseline functional assessments. If denied, California's Independent Medical Review (IMR) overturns 55-70% of medical necessity denials. First step: Have your metabolic specialist submit PA through UHC Provider Portal with enzyme testing, 6-minute walk test results, and detailed medical necessity letter. For urgent cases, request expedited review within 72 hours.

Table of Contents

Why Myths About Naglazyme Coverage Persist

Getting Naglazyme (galsulfase) approved can feel overwhelming, especially when dealing with a rare disease like MPS VI (Maroteaux-Lamy syndrome). Misinformation spreads quickly in online forums and support groups, often from well-meaning families sharing outdated experiences or incomplete information.

The reality is that UnitedHealthcare does cover Naglazyme when medical necessity criteria are met, but the process requires specific documentation and follows strict protocols. Understanding what's myth versus fact can save you months of delays and unnecessary stress.

Counterforce Health helps patients navigate these complex approval processes by analyzing denial letters, identifying missing documentation, and crafting evidence-backed appeals that align with each insurer's specific requirements.

Note: This information applies to UnitedHealthcare commercial and exchange plans in California. Medicare Advantage and employer-specific plans may have different requirements.

Myth vs. Fact: Common Misconceptions

Myth 1: "If my doctor prescribes Naglazyme, UnitedHealthcare has to cover it"

Fact: UnitedHealthcare requires prior authorization for Naglazyme regardless of medical necessity. Even with a prescription, coverage depends on meeting specific diagnostic and clinical criteria.

Myth 2: "Rare disease drugs are automatically approved"

Fact: Orphan drug status doesn't guarantee coverage. UnitedHealthcare's Medical Therapies for Enzyme Deficiencies policy states that "FDA approval alone is not a basis for coverage." Clinical criteria and prior authorization still apply.

Myth 3: "I can't appeal if UnitedHealthcare says Naglazyme is experimental"

Fact: Naglazyme has full FDA approval for MPS VI. If denied as experimental, this is often an error or misapplication of policy. California's Independent Medical Review frequently overturns such denials.

Myth 4: "Home infusion isn't covered"

Fact: UnitedHealthcare covers Naglazyme in multiple settings, including home infusion once patients are stable. Site-of-care restrictions may apply, but exceptions are available with clinical justification.

Myth 5: "Appeals take too long for urgent cases"

Fact: California law requires expedited appeals within 72 hours when delay could seriously jeopardize health. This often applies to enzyme replacement therapy for progressive conditions.

Myth 6: "UnitedHealthcare always denies expensive drugs first"

Fact: While utilization management is common, complete documentation addressing all policy criteria significantly improves first-pass approval rates. Missing enzyme testing or functional assessments are the most common denial reasons.

Myth 7: "I need to try other treatments first (step therapy)"

Fact: Naglazyme is the only FDA-approved enzyme replacement therapy for MPS VI. Step therapy typically doesn't apply when no therapeutic alternatives exist for the specific condition.

Myth 8: "BioMarin patient assistance only helps with copays"

Fact: BioMarin's support programs include benefits investigation, prior authorization assistance, appeals support, and free drug programs for eligible patients.

What Actually Influences UnitedHealthcare Approval

Required Documentation Checklist

Requirement What UnitedHealthcare Needs Where to Get It
Confirmed MPS VI Diagnosis Enzyme assay showing arylsulfatase B deficiency Genetic/metabolic lab
Genetic Testing ARSB gene mutations (if available) Clinical genetics lab
Specialist Involvement Prescription from metabolic/genetic specialist MPS treatment center
Baseline Function 6-minute walk test or stair-climbing assessment Clinic visit
Clinical Manifestations Documented symptoms and organ involvement Specialist notes
Dosing Plan 1 mg/kg IV weekly per FDA label Treatment plan

The OptumRx Prior Authorization Process

UnitedHealthcare processes Naglazyme requests through OptumRx, their pharmacy benefit manager. The typical workflow:

  1. Initial Review (5-15 business days): OptumRx clinical pharmacists evaluate against policy criteria
  2. Peer-to-Peer Option: If initially denied, prescribers can request physician-to-physician review
  3. Appeal Process: Standard appeals within 30 days, expedited within 72 hours for urgent cases

Medical Necessity Language That Works

Successful prior authorization letters typically include:

  • Specific diagnosis: "Patient has biochemically confirmed mucopolysaccharidosis type VI with arylsulfatase B deficiency"
  • FDA indication alignment: "Naglazyme is FDA-approved for MPS VI to improve walking and stair-climbing capacity"
  • No alternatives: "No other disease-modifying therapy is available for MPS VI"
  • Progressive nature: "Without treatment, expect irreversible multisystem decline"

Avoid These Preventable Mistakes

1. Submitting Incomplete Enzyme Testing

The Problem: Many denials cite "diagnosis not confirmed" when enzyme assay results are missing or unclear.

The Fix: Ensure lab reports clearly show arylsulfatase B deficiency with reference ranges. If genetic testing was done instead, include both genetic and enzyme data when possible.

2. Missing Baseline Functional Assessments

The Problem: UnitedHealthcare requires objective measures to evaluate treatment benefit.

The Fix: Complete 6-minute walk test, stair-climbing assessment, or other standardized functional measures before submitting PA request.

3. Wrong Billing Channel

The Problem: Naglazyme may be covered under medical or pharmacy benefit depending on administration site.

The Fix: Verify benefit structure before submission. Hospital outpatient typically bills medical benefit (UnitedHealthcare), while home infusion often uses pharmacy benefit (OptumRx).

4. Generic Medical Necessity Letters

The Problem: Form letters that don't address UnitedHealthcare's specific policy criteria.

The Fix: Reference UnitedHealthcare's enzyme replacement therapy policy directly and address each criterion.

5. Not Requesting Expedited Review When Appropriate

The Problem: Using standard timelines when clinical urgency exists.

The Fix: For progressive conditions like MPS VI, document why delay could jeopardize health and request expedited processing.

Quick Action Plan: Three Steps to Take Today

Step 1: Verify Your Coverage Details

  • Log into your UnitedHealthcare member portal
  • Check if Naglazyme appears on your plan's formulary
  • Note any prior authorization requirements or tier placement
  • Confirm whether OptumRx manages your prescription benefits

Step 2: Gather Essential Documentation

Contact your MPS treatment center to collect:

  • Enzyme assay results showing arylsulfatase B deficiency
  • Genetic testing report (if available)
  • Baseline functional assessments (6-minute walk test, etc.)
  • Complete medical records documenting MPS VI manifestations

Step 3: Connect with BioMarin Support

Call BioMarin's patient support program to:

  • Verify your insurance benefits and coverage pathway
  • Get assistance with prior authorization submission
  • Apply for copay assistance or patient assistance programs
  • Coordinate with specialty pharmacy if needed
Tip: Keep detailed records of all communications, including dates, names, and reference numbers for follow-up.

California Appeals: Your Safety Net

California offers some of the strongest patient protections in the nation for insurance appeals, particularly through the Department of Managed Health Care (DMHC).

Independent Medical Review (IMR) Success Rates

California's IMR system has historically overturned 55-70% of medical necessity denials, making it a powerful tool for Naglazyme appeals.

Appeal Timeline for UnitedHealthcare in California

Level Timeline Decision Maker How to File
Internal Appeal 30 days standard, 72 hours expedited UnitedHealthcare Member/provider portal
DMHC IMR 45 days standard, 7 days expedited Independent physicians Online application

When to File an IMR

You can request an Independent Medical Review if:

  • UnitedHealthcare denies Naglazyme as "not medically necessary"
  • Internal appeals are denied or take longer than required timeframes
  • There's a dispute about experimental/investigational designation

No cost to patients: California law prohibits charging patients for IMR reviews.

From our advocates: We've seen many Naglazyme denials overturned at IMR when families submitted comprehensive documentation including enzyme testing, specialist letters citing published outcomes data, and evidence that delay would cause irreversible progression. The key is framing the request around medical necessity rather than cost concerns.

Resources and Patient Support

Official UnitedHealthcare Resources

California State Resources

BioMarin Support Programs

Specialty Organizations

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage varies by plan and individual circumstances. Always consult with your healthcare provider and insurance company for specific coverage decisions.

For complex cases requiring detailed appeals strategy, Counterforce Health specializes in turning insurance denials into successful approvals through evidence-based advocacy and payer-specific expertise.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.